World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.

Item

http://www.wikidata.org/entity/Q34315836

Q34315836

about

Q24197685 Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment Effective Strategies for Nurses Empowering Clients With Schizophrenia: Medication Use as a Tool in Recovery.A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration.Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.Phadiatop Seropositivity in Schizophrenia Patients and Controls: A Preliminary Study.The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.The impact of antipsychotic polytherapy costs in the public health care in Sao Paulo, Brazil Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis.A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Holistic Consideration of Patients with Schizophrenia to Improve Medication Adherence and Outcomes.Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials Epidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review.Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis Psychoeducational and Cognitive Behavioral Treatment Programs: Implementation and Evaluation From 1995 to 2015 in Kraepelin's Former Hospital.Antipsychotics and the Risks of Sudden Cardiac Death and All-Cause Death: Cohort Studies in Medicaid and Dually-Eligible Medicaid-Medicare Beneficiaries of Five States.Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics.Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode.The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole.Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors.New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways.Antipsychotic treatment modulates glutamate transport and NMDA receptor expression.Antipsychotic switching in schizoaffective disorder: A systematic review.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactatio Glutamatergic agents for schizophrenia: current evidence and perspectives.

P2860

Q24197685-38552BD3-BAD6-4D29-B10B-8C0BFE3D8EB2 Q26752965-9E248733-3B12-44FB-8D32-E8FECED4DD52 Q26772965-906CBD41-044D-4199-A8F0-BDDAB43CD299 Q27015872-E3901034-0F3B-4813-8EFC-637E72002444 Q30276915-A67574E5-A1A6-4584-B9EB-3982BE43B6BD Q30353864-E205B07E-2215-4CE6-ACE1-B3C5329DC613 Q30627430-0326431C-FC99-484C-8019-2BE9D690EDD9 Q30657759-E1650190-02DD-4C79-BFFD-8D1CF2A38276 Q33614458-137DB4BD-7479-4A43-A8D7-4B9B649E6F67 Q33625354-43120322-B35E-40A8-827E-95A05BC229D7 Q33878816-3A999EE7-ABE1-4308-91A6-CFB5435F9856 Q34248044-9F3C2D92-B89A-4401-AF50-CA25A6AC0998 Q34293899-B16EE66D-547B-4394-933D-7CEED2D649E7 Q34330678-8A3555EA-7748-4910-8624-806ED58C9C19 Q34385689-DA8CC037-6710-47AC-95C3-DB0FFFF44AAA Q35021287-13748B12-4417-4688-8618-9D369CB0D209 Q35073474-DE9F5608-6B14-4EAF-AED9-CF2501F4AFE4 Q35324015-1E5821D7-51C6-4395-ADB4-36164CE0FB1C Q35683821-17DEB883-1E40-4B25-A186-63C1A82D6967 Q35683860-D11032AF-91F7-4D03-8F94-6749377C7168 Q35709035-6CE1BE86-1121-4CF2-B08E-EF41BE510BA0 Q35754726-04D491A0-577D-4453-9842-A63F38969237 Q35965617-504650CF-1214-4462-A8CD-9541E41401B6 Q36001512-3819547B-7FAC-4783-B69A-9F27553A1E43 Q36232324-F60AFF82-4CD0-44D3-9800-F000A18D3B12 Q36467615-88859CB3-65A7-407B-BD9F-01D17E05572F Q36550998-91C1C085-60E3-4F66-8DE7-F5CD4FA759A8 Q37124968-6C639DEF-41F7-4199-BB0A-2D28EEECA42A Q37156481-08DA3101-CEC8-40D0-8CB0-325D1734BAC4 Q37465729-A37EFF56-BE6F-49C6-943D-BEF5E9AE583D Q37547469-A498F062-FC5B-4426-A50F-E55C14E76A4F Q37576827-42B96006-8776-48D1-87CD-D32580A58304 Q37649902-64EA63E4-5BC3-4A69-B485-D2FEE1E1E683 Q37735342-3262BF72-20E2-45F9-9E54-D40592A3ED16 Q38079160-6D30FA4E-5450-4BA1-820E-F839CF7B9E54 Q38233857-794D5663-73D4-497F-A757-341CF185B5CF Q38248566-6E6F21D7-C161-4628-B772-C86B1E79649E Q38370545-45315565-E76E-42E6-96D8-D96BE8EE8174 Q38395937-39AA85FE-EF31-4181-937E-513AA8BFD99D Q38444551-FCCC5119-AAC6-40D5-AE6C-C605AFD98B60

P2860

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.

Item

http://www.wikidata.org/entity/Q34315836

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu